(firstQuint)A Study To Evaluate ASN002 In Subjects With Atopic Dermatitis.

 This study is a dose escalation study to determine a safe and tolerable dose of ASN002 for people with moderate to severe atopic dermatitis.

 This study will also characterize the pharmacokinetics and pharmacodynamics of ASN002 through blood sampling and skin biopsies.

 Subjects will also be assessed for improvement in their atopic dermatitis.

 There will be a screening period (up to 30 days) and a treatment period for 4 weeks with a 14 day follow up with an end-of-study visit.

.

 A Study To Evaluate ASN002 In Subjects With Atopic Dermatitis@highlight

This is a dose escalation study to test the safety, tolerability and preliminary efficacy of ASN002 in people with moderate to severe atopic dermatitis (AD).

